UBS Raises Alnylam Pharmaceuticals' Price Target to $308 From $288, Buy Rating Maintained
UBS Raises Alnylam Pharmaceuticals' Price Target to $308 From $288, Buy Rating Maintained
瑞银将阿里拉姆制药的目标价从288美元上调至308美元,保持买入评级。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册